New-Generation Drug-Eluting Stents for Left Main In-Stent Restenosis
Authors:
- Gennaro GiustinoGGGennaro Giustino
- Akihito TanakaATAkihito Tanaka
- Andrejs ErglisAEAndrejs Erglis
- Marie Claude MoriceMMMarie Claude Morice
- Nicolas M. Van MieghemNMNicolas M. Van Mieghem
- Emanuele MeligaEMEmanuele Meliga
- Fabrizio D’aScenzoFDFabrizio D’aScenzo
- Giulio G. StefaniniGSGiulio G. Stefanini
- Davide CapodannoDCDavide Capodanno
- Alaide ChieffoACAlaide Chieffo
- 1 December 2018
- journal article
- letter
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 11 (23) , 2438-2440
Abstract
No abstract availableFunding Information
- Edwards Lifesciences
This publication has 3 references indexed in Scilit:
- The DELTA 2 RegistryJACC: Cardiovascular Interventions, 2017
- Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents–Cardiogroup III Study)The American Journal of Cardiology, 2017
- Incidence, Predictors, Treatment, and Long-Term Prognosis of Patients With Restenosis After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery DiseaseJACC, 2011